Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717334 | 0.98 | KMT2A (0.35) | KMT2AKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL721733 | 0.95 | KMT2A (0.35) | KMT2AKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL720539 | 0.91 | MAPT (0.36) | KMT2AKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL718268 | 0.88 | PRSS1 (0.36) | KMT2ANPC1RAB9ATP53POLB | |
| SCHEMBL720867 | 0.88 | KMT2A (0.34) | KMT2AKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL716683 | 0.88 | NPC1 (0.43) | KMT2AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL718752 | 0.87 | KMT2A (0.36) | KMT2AKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL719676 | 0.87 | NPC1 (0.34) | KMT2AKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL719677 | 0.87 | NPC1 (0.34) | KMT2AMEN1NPC1RAB9ATP53 | |
| SCHEMBL720981 | 0.86 | KMT2A (0.34) | KMT2AKDM4EALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | KMT2A 1298/4885KDM4E 1907/4885ALDH1A1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.